"Race is such a dominant category in the cognitive field that it can leave its own indelible mark once given even the temporary imprimatur of scientific legitimacy by molecular genetics," Duster writes, expressing concern for the precedent the NitroMed study may set.
However, Duster encourages continued research to match genetics and medical treatment.
"An increased understanding of genetic diversity will help scientists doing gene-association studies by identifying new variants and reducing the likelihood of false-positive associations," he writes. "The hope is that it may aid scientists to identify medically relevant genes for diseases."
Initially, the FDA rejected its use to treat heart disease because of its ineffectiveness among the general population. However, the company began testing BiDil exclusively on blacks with FDA approvalafter theorizing that the drug's effect on nitric-oxide deficiency, which is more common in black heart-failure patients than in non-blacks, would be beneficial to a targeted racial population. NitroMed reported effectiveness of the BiDil in its clinical trial of 400 black women and 600 black men.
NitroMed, which intends to market the drug to African Americans after FDA approval, has noted that African Americans between the ages of 45 and 64 are two-and-a-half times more likely to die from hear
Contact: James Devitt
New York University